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David Rubenstein7, David Woodley8, Carmela Vittorio1, Benjamin B. Werth1, Erik A. Williams1,
Lynne Taylor9, Andrea B. Troxel9 and Victoria P. Werth1,10
A major obstacle in performing multicenter controlled trials for pemphigus is the lack of a validated disease
activity scoring system. Here, we assess the reliability and convergent validity of the PDAI (pemphigus disease area
index). A group of 10 dermatologists scored 15 patients with pemphigus to estimate the inter- and intra-rater
reliability of the PDAI and the recently described ABSIS (autoimmune bullous skin disorder intensity score)
instrument. To assess convergent validity, these tools were also correlated with the Physician’s Global Assessment
(PGA). Reliability studies demonstrated an intra-class correlation coefficient (ICC) for inter-rater reliability of 0.76
(95% confirdence interval (CI)¼ 0.61–0.91) for the PDAI and 0.77 (0.63–0.91) for the ABSIS. The tools differed most in
reliability of assessing skin activity, with an ICC of 0.39 (0.17–0.60) for the ABSIS and 0.86 (0.76–0.95) for the PDAI.
Intra-rater test-retest reliability demonstrated an ICC of 0.98 (0.96–1.0) for the PDAI and 0.80 (0.65–0.96) for the
ABSIS. The PDAI also correlated more closely with the PGA. We conclude that the PDAI is more reproducible and
correlates better with physician impression of extent. Subset analysis suggests that for this population of mild-to-
moderate disease activity, the PDAI captures more variability in cutaneous disease than the ABSIS.
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INTRODUCTION
Our scientific understanding of the pathogenesis of pemphigus
has greatly improved in recent years. As we try to evaluate
therapeutic options to develop treatment paradigms for
pemphigus, however, a major obstacle in performing large,
multicenter controlled trials is the lack of a validated scoring
system to rate disease activity. An ongoing Cochrane review of
clinical trials studying pemphigus has revealed a total of 116
outcome measures described in 96 articles over the past 25
years (Martin and Murrell, 2006). This lack of uniformity makes
it challenging to compare treatment regimens and to choose
among therapeutic options. Here, we evaluate a new measure-
ment instrument (PDAI –pemphigus disease area index), which
was developed by the International Pemphigus Committee in an
effort to create a tool that can reliably capture all ranges of
cutaneous and mucosal disease extent, and we compare it with
a recently developed scoring system, the autoimmune bullous
skin disorder intensity score (ABSIS), which has not yet been
evaluated for inter-rater or intra-rater reliability. We also
compared these two instruments to the Physician’s Global
Assessment (PGA), an instrument often used for inflammatory
skin disease, although it has not been specifically validated for
pemphigus. Validated scoring systems are needed to allow
proper evaluation of potential therapies, as well as to compare
results from different trials. These, combined with other
evaluations, including laboratory testing of autoantibodies and
quality of life measures, will help determine the efficacy of
therapies. The goal of these instruments is to allow standardized
assessment of disease extent in patients with pemphigus in an
effort to facilitate physicians to conduct multicenter trials.
RESULTS
Distribution of scores
The PDAI total score was approximately normally distributed
with total scores ranging from 0 to 44 (mean 13.1±9.03) out
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of a possible 263 maximum score for the instrument. The
interquartile range (25–75% of scores) for the PDAI total score
was 6.3–19. The PDAI skin activity subscore ranged from 0 to
28.3 (mean 5.57±6.48) out of a possible 130, with an
interquartile range of 0–8.0. The PDAI mucous membrane
activity subscore ranged from 0 to 40 (mean 4.62±7.55) out
of a possible 120, with an interquartile range of 0–6.0. The
PDAI total activity subscores (skin plus mucous membrane)
ranged from 0 to 43 (mean 10.22±8.14) out of a possible
250, with an interquartile range of 4.2–14. The PDAI damage
subscore ranged from 0 to 12 (mean 2.91±3.28) out of a
possible 13, with an interquartile range of 0–6.0.
The ABSIS scores were skewed toward the low end of the
scale, with 50% of the scores between 0 and 4. ABSIS total
scores ranged from 0 to 38 out of a possible 206, with a
median score of 4.0 and an interquartile range of 2–8.5.
ABSIS skin involvement subscores ranged from 0 to 30 out of
a possible 150, with a median score of 1.0 and an
interquartile range of 0–3.5. ABSIS oral involvement subscore
ranged from 0 to 11 out of a possible 11, with a median score
of 1.0 and an interquartile range of 0–4.0. ABSIS oral
subjective discomfort subscores ranged from 0 to 35 out of
a possible 45, with a median score of 0.0 and an interquartile
range of 0–0 (8% of the scores were zero). Notably, 7 out of
10 raters recorded values of ‘‘less than 1%’’ when comment-
ing on body surface area involved with pemphigus. These
values were treated as if they were exactly 1%, as it is
impossible to quantify a specific value for ‘‘less than 1%.’’
The PGA total score had an approximately normal
distribution. The total scores ranged from 0 to 8.0 (mean
2.54±1.58) out of a possible 10, with an interquartile range
of 1–3.0.
Reliability
Test-retest reliability. Physicians’ agreement between their
initial scoring and re-rating of the same subject showed an
overall intra-class correlation coefficient (ICC) (95% con-
fidence interval (CI)) of 0.98 (0.96–1.0) for the PDAI, 0.80
(0.65–0.96) for the ABSIS, and 0.75 (0.55–0.94) for the PGA
(Table 1). The ICC (95% CI) for the PDAI skin activity was
0.98 (0.96–1.0), for mucous membrane activity was 0.98
(0.97–1.0), and for damage was 0.89 (0.80–0.98). The ICC for
the ABSIS skin involvement was 0.87 (0.77–0.98), for
mucosal involvement was 0.99 (0.97–1.0), and for subjective
discomfort it was not calculable (due to too little variability
among subjects). The test-retest correlation (Spearman’s n˜)
was rsp¼ 0.94 (0.86–1.0) for the total PDAI, and rsp¼0.91
(0.79–1.0) for the total ABSIS scale.
Inter-rater reliability. The consistency among physicians’
rating of subjects using each tool had an overall ICC of 0.76
(0.61–0.91) for the PDAI, 0.77 (0.63–0.91) for the ABSIS, and
0.44 (0.22–0.65) for the PGA (Table 2). The ICC for the PDAI
skin activity was 0.86 (0.76–0.95), for mucous membrane
activity was 0.84 (0.73–0.95), for total activity (skin and
mucous membrane) was 0.77 (0.62–0.91), and for damage
was 0.69 (0.52–0.86). The ICC for ABSIS skin involvement
was 0.39 (0.17–0.60), for mucosal involvement was 0.85
(0.75–0.95), and for subjective discomfort was 0.89
(0.82–0.97).
Validity: correlation with the PGA
The PDAI and ABSIS scores were then correlated with the
PGA. The PDAI had a correlation of 0.60 (0.49–0.71)
compared with the ABSIS correlation of 0.43 (0.30–0.55).
Figure 1 provides the mean PDAI and ABSIS score for each
PGA. There is a statistically significant linear trend between
PGA with PDAI (F¼ 49.75; d.f.¼1; Po0.0001) and PGA
with ABSIS (F¼ 12.38; d.f.¼ 1; Po0.0006). The mean scores
for both PDAI and ABSIS increase (indicating a worsening
condition) as PGA increases. Assessing pair wise comparisons
of PDAI levels at different levels of PGA, several comparisons
(PGA 1 vs 3, 1 vs 4, 2 vs 4, 3 vs 4) are statistically significantly
different. For ABSIS scores, only one pair (PGA 1 vs 3) shows
a statistically significant difference.
Time for instrument completion
The mean time for the PDAI was 4.7minutes (±0.18) and for
the ABSIS was 3.9minutes (±0.18); PGA time was not
recorded.
DISCUSSION
As both scoring systems were heavily weighted toward the
low end of their respective scales, the PDAI data was
Table 1. Intra-rater test-retest reliability (n=20)
Score name (range) Intra-rater ICC (95% CI)
Total ABSIS 0.80
(0–206) (0.65–0.96)
Skin involvement 0.87
(0–150) (0.77–0.98)
Oral involvement 0.99
(0–11) (0.97–1.0)
Subjective discomfort 1
(0–45)
Total PDAI 0.98
(0–263) (0.96–1.0)
Skin activity 0.98
(0–130) (0.95–1.0)
Mucous membrane activity 0.98
(0–120) (0.97–1.0)
Total activity 0.98
(0–250) (0.96–1.0)
Damage 0.89
(0–13) (0.80–0.98)
Physician’s global assessment 0.75
(0–10) (0.55–0.94)
1Variability among persons too small to reliably estimate ICC.
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normally distributed, whereas the ABSIS data was non-
normal and skewed to the left. The inter-rater reliability for
both tools was similar, with an ICC of 0.76 for the PDAI
compared with 0.77 for the ABSIS. The comparison of skin
activity between the two instruments, however, shows that
the PDAI skin activity had an ICC of 0.86 compared with 0.39
for the ABSIS. The ABSIS scoring tool achieves much of its
inter-rater reliability from the subjective component, patient
report of discomfort with foods, as opposed to the objective,
physician-dependent portion of the scaling system. The
discrepancy between skin activity ICC scores suggests that
at mild-to-moderate levels of disease, such as those
represented in this study population, the PDAI may be better
able to detect small differences in pemphigus cutaneous
disease extent. This is further suggested by the distribution of
scores, with the PDAI allowing for a normal distribution of
scores even in this limited population of mild-to-moderate
disease activity, although the ABSIS data was skewed to the
left. In fact, many of the raters reported difficulty in grading
the patients using the ABSIS scale, and 7 out of 10 raters
recorded values less than the minimum 1% (all such scores
were treated as 1% for study statistics), which suggests that
the ABSIS as designed may be failing to capture clinically
detectable differences in disease activity. In the original
ABSIS publication, the authors note that using ‘‘the rule of
nine’’ to calculate body surface area can be difficult and lead
to inter-rater disagreement when scorers are untrained; in this
study, all of the raters were experienced dermatologists
familiar with ‘‘the rule of nine.’’ However, there is evidence
that using skin area assessments to measure inflammatory
skin disease can be difficult, even for physicians (Tilin-Grosse
and Rees, 1993; Charman et al., 1999; Charman and
Williams, 2000).
The intra-rater reliability was examined by having
physicians re-evaluate patients they had previously scored,
using both metrics again. The test-retest analysis showed an
overall ICC of 0.98 (0.96–1.0) for the PDAI, 0.80 (0.65–0.96)
for the ABSIS, and 0.75 (0.55–0.94) for the PGA. This suggests
that not only was the PDAI more consistent among multiple
raters, but that the scores were more reproducible for each
individual physician rater as well.
After the patient scoring, physician feedback was ob-
tained. These responses suggested that the majority of
physicians involved in this study felt that both the PDAI
and ABSIS were too difficult to be incorporated into routine
practice, but that the PDAI allowed for more accurate
representation of the spectrum of disease extent. Many
physicians had trouble with the ABSIS subjective discomfort
component. Some physicians felt that the PGA was sufficient,
although the lack of inter-rater (ICC¼ 0.44) or intra-rater
(ICC¼0.75) reliability seen in this study suggests that the
PGA is a poor tool to objectively assess pemphigus disease
Table 2. Inter-rater reliability: score distribution and convergent validity
Median (IQR) Inter-rater ICC PGA rsp
Score name (Range) Range Mean±SD (95% CI) (95% CI)
Total ABSIS 0–38 4.0 (2.0–8.5) 0.77 0.43
(0–206) 6.91±7.52 (0.63–0.91) (0.30–0.55)
Skin involvement 0–30 1.0 (0–3.5) 0.39 0.45
(0–150) 2.48±3.79 (0.17–0.60) (0.32–0.58)
Oral involvement 0–11 1.0 (0–4.0) 0.85 0.02
(0–11) 2.04±2.57 (0.75–0.95) (0.19–0.15)
Oral subjective discomfort 0–35 0.0 (0–0.0) 0.89 0.10
(0–45) 2.39±6.12 (0.82–0.97) (0.05–0.26)
Total PDAI 0–44 10.8 (6.3–19.0) 0.76 0.60
(0–263) 13.1±9.03 (0.61–0.91) (0.49–0.71)
Skin activity 0–28.3 3.3 (0–8.0) 0.86 0.48
(0–130) 5.57±6.48 (0.76–0.95) (0.35–0.61)
Mucous membrane activity 0–40 1.0 (0–6.0) 0.84 0.03
(0–120) 4.62±7.55 (0.73–0.95) (0.14–0.20)
Total activity 0–43 8.0 (4.2–14.0) 0.77 0.60
(0–250) 10.22±8.14 (0.62–0.91) (0.49–0.71)
Damage 0–12 1.0 (0–6.0) 0.69 0.26
(0–13) 2.91±3.28 (0.52–0.86) (0.11–0.41)
Physician’s global assessment 0–8 2.0 (1.0–3.0) 0.44
(0–10) 2.54±1.58 (0.22–0.65)
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activity. Notably, although the PDAI took longer to complete
on average, the time to use either tool was not markedly
different (4.7minutes for the PDAI, 3.9minutes for the
ABSIS).
The patients evaluated in this study had limited disease
extent. For both instruments, the highest score (representing
most severe disease extent) was less than 25% of the
maximum possible score. This limits the conclusions that
can be drawn from these data. However, at the low end of the
spectrum of pemphigus disease extent, it appears that the
PDAI is able to capture small differences in disease extent.
The ability of the PDAI to allow raters to consistently assess
small differences in even mild disease activity suggests that
the PDAI may represent a scoring system capable of allowing
Figure 1. ABSIS scoring sheet, adapted from Pfutze et al., 2007.
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researchers to follow disease activity in a clinical trial setting
and compare data among individual physicians as well as
across multiple research centers. Furthermore, it is our belief
that given the nature of pemphigus, which tends to be
dramatically responsive to glucocorticoid therapy, it is
crucial that an instrument to monitor disease be able to
detect activity at the low end of the disease spectrum.
Notably, both instruments correlated well with the PGA at
PGA scores of 0–4, with a statistically significant linear trend
(data not shown). The small number of patients with more
severe disease extent (with only 19 PGA scores rated as a 5 or
higher, out of 150 total scores) limits the ability to draw
conclusions at more severe levels of disease.
One of the limitations of this study is that the patients
evaluated represented the low end of the disease activity
spectrum. Therefore, these results cannot be extrapolated to
patients with more severe disease. We are currently
performing additional studies to evaluate the PDAI and
validate it for use in more severe disease populations. A
portion of this study will take place using web-based digital
photographs to allow for representation of a wider spectrum
of disease and to allow members of the International
Pemphigus Community to participate in the evaluation and
validation of these scoring instruments.
In conclusion, the PDAI shows reasonable convergent
validity and was found to be a reliable, quick, and easy-to-use
method to capture the extent of skin and mucosal lesions in
patients with mild-to-moderate pemphigus vulgaris and pem-
phigus foliaceus. It should be considered as a possible outcome
measure that needs further study to examine responsiveness.
MATERIALS AND METHODS
Ten physicians and fifteen patients were brought to the dermatology
clinic at the Hospital of the University of Pennsylvania on 1 day to
complete this study. In the morning of the study day, physicians
completed a training session on the PDAI, ABSIS, and Physician
Global Assesment (PGA) with visual images of skin manifestations of
pemphigus vulgaris, pemphigus foliaceus, and paraneoplastic
pemphigus to familiarize themselves with the three instruments
and discuss scoring methods. Physicians and patients were divided
into two groups. Physicians scored the first group of patients using
the ABSIS scale first, followed by the PDAI and PGA. They reversed
the order of instruments for scoring the second group. Physicians
were instructed to individually document their start and stop times
for each tool. Physicians rotated among patient rooms, with only one
physician and patient in a room at any one time. Each physician then
returned to the original group and re-rated two patients selected at
random by patient availability, with at least 2 hours between the
initial and subsequent re-rating. To minimize recall, neither the
physicians nor patients were told at the beginning of the study that
there would be a re-scoring session at the end to assess intra-rater
reliability. Re-rating was carried out on a random basis based on
patient availability, not requiring each patient to be re-rated but
rather requiring each physician to re-rate two patients. Of the 15
patients, all but 4 were re-rated at least once; 6 patients were re-
rated by 1 physician, 3 patients were re-rated by 2 physicians,
1 patient was re-rated by 3 physicians, and 1 patient was re-rated by
5 physicians.
Patients
The patients were volunteers from the outpatient clinic of the
Department of Dermatology of the University of Pennsylvania, a
tertiary care center in Philadelphia, Pennsylvania, or members of the
International Pemphigus and Pemphigoid Foundation (IPPF) who
volunteered to participate. All patients had a clinical exam,
histological result from a skin biopsy, and immunofluorescence
studies consistent with a diagnosis of pemphigus vulgaris, pemphi-
gus foliaceus, or paraneoplastic pemphigus.
Physicians
All physicians were board-certified dermatologists with extensive
experience diagnosing, treating, and managing patients with
pemphigus. Physician questions regarding the instruments were
addressed in a group discussion mediated by the principal
investigator immediately before the study commencement. All
physicians scored all 15 patients and all physicians re-scored two
patients. At the end of the session, all physicians were polled for
feedback regarding both scoring tools.
Description of instruments
The purpose of these instruments is to allow clinicians and
researchers to measure disease extent and to potentially monitor
patients longitudinally.
ABSIS
The ABSIS instrument was developed by Pfutze et al. (2007). Using
body surface area and lesion type as weighting factors, the ABSIS
incorporates skin activity and oral involvement with a subjective
severity scale based on discomfort during eating and drinking. Using
higher scores to denote worse disease, the ABSIS has a possible
scoring range of 0–206, with 150 points for skin involvement,
11 points for oral involvement, and 45 points for subjective
discomfort (Figure 1).
PDAI
The PDAI instrument used in this study was developed by leading
academic dermatologists with extensive experience in the manage-
ment of pemphigus. Starting in 2005, there were several of meetings
of the International Pemphigus Committee to develop a tool to
measure pemphigus disease activity; the PDAI is the result of an
international consensus (Murrell et al., 2008). Using higher scores to
denote worse disease, the PDAI has a total possible score ranging
from 0 to 263, with 250 points representing disease activity (120
points for skin activity, 10 points for scalp activity, and 120 points for
mucosal activity) and 13 points representing disease damage
(Figure 2). The tool is used by examining each area as indicated,
with scores assigned to each anatomic region based on number and
size of lesions in that region. The skin, scalp, and mucosa is scored
separately, and there is a damage component incorporated to
capture areas affected by pemphigus, such as patches of post-
inflammatory hyperpigmentation, which lacking primary lesions.
When raters scored an anatomic region with a 1 (1–3 lesions, none
greater than 2 cm), they also recorded the number of lesions at that
site, ranging from one to three lesions. This lesion count was
incorporated into the scoring by giving each region a score of 1 if
1 lesion was present, a score of 1.3 if 2 lesions were present, and a
score of 1.6 if 3 lesions were present.
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PGA
The PGA is a ten-point visual analog scale ranging from 0¼ perfect
health to 10¼worst skin condition imaginable (Figure 3). This
scoring system allows physicians to rate disease activity by general
overall impression; its use has been validated in studying psoriasis
(Langley and Ellis, 2004), and has been used in studies of patients
with cutaneous lymphoma (Heald et al., 2003), eczema (Guzzo
et al., 1991), dermatomyositis (Hundley et al., 2006), and other
inflammatory dermatoses. Because there is no gold-standard
instrument used to assess pemphigus disease activity, we used the
PGA as part of an assessment of convergent validity, expecting a
positive correlation between the PGA and both the PDAI and ABSIS.
Statistical methods
Scale distribution. The summary statistics were used to describe
the sample’s distribution of scores for each instrument; the
Pemphigus disease area index (PDAI)
Skin Activity Damage
Figure 2. Pemphigus Disease Area Index (PDAI).
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Shapiro–Wilk’s test was applied to assess normality of the
distributions.
Reliability and validity. To analyze and describe the change in
physician scores from the first to second rating on the same patient, test-
retest intra-rater reliability was assessed using the ICC. The Spearman’s
r correlation was also assessed for all of the test-rest data. Inter-rater
reliability was also assessed using ICC. All ICCs were calculated using
the one-way random-effect ANOVA model. On the basis of earlier
research, an ICC of 0.5–0.7 is considered minimally acceptable, while
an ICC above 0.81 is considered excellent (Shrout and Fleiss, 1979).
Validity was assessed using the Spearman’s n˜ to correlate the
PGA to each instrument (PDAI and ABSIS) as a means of identifying
whether the tools were appropriately reflecting the current overall
level of disease. To assess whether the instruments showed linear
trends over increasing intervals of the PGA, the GLM-ANOVA F-test
for linear trends was used, with the Scheffe test to adjust for multiple
pair wise comparisons. Subjects with PGA levels of 1, 2, 3, and
4 were included in the analysis, and those with levels 5 through
10 were omitted due to their small sample size (i.e. fewer than
10 subject scores in this range).
Time for instrument completion. All physicians individually
recorded the time they spent in each patient’s room, as well as the
start and end time for each instrument. The means and SEs were
computed for the PDAI and ABSIS instruments.
These investigations were performed with institutional approval
through the University of Pennsylvania institutional review board in
adherence with the Declaration of Helsinki Principles Guidelines.
Written informed patient consent was obtained from all participants.
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Figure 3. Physician’s Global Assessment.
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